Upgrade to SI Premium - Free Trial

Novartis (NVS)

83.54 -1.38 (1.63%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/27/21 *Est.)
- M&A (3/31/20 *Est)

Latest Headlines

Form 6-K NOVARTIS AG For: Oct 25 October 25, 2021 6:05 AM - SEC Filing Credit Suisse Reiterates Neutral Rating on Novartis (NOVN:SW) (NVS) October 15, 2021 6:02 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Lowered to CHF88 at Berenberg October 12, 2021 10:33 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Lowered to CHF92 at UBS October 8, 2021 8:20 AM - StreetInsider Cathie Wood's ARK Sold Another $265M in Tesla (TSLA) Stock on Tuesday September 29, 2021 6:53 AM - StreetInsider Cathie Wood's ARK Buys More Robinhood (HOOD) and Coinbase (COIN) Stock, Trims More Tesla (TSLA) September 28, 2021 7:19 AM - StreetInsider Bernstein Reiterates Market Perform Rating on Novartis (NOVN:SW) (NVS) September 27, 2021 11:38 AM - StreetInsider Positive Combo Data at ESMO Offers Positive Readthroughs to Surface Oncology (SURF) Adenosine Pathway Assets - BTIG September 20, 2021 8:44 AM - StreetInsider Deutsche Bank Downgrades Novartis (NOVN:SW) (NVS) to Sell September 20, 2021 7:46 AM - StreetInsider Novartis (NVS) Presents New Data Showing Kisqali Demonstrated Longest Median Overall Survival Ever in HR+/HER2- Advanced Breast Cancer September 19, 2021 6:26 PM - StreetInsider Deutsche Bank Reiterates Hold Rating on Novartis (NOVN:SW) (NVS) September 19, 2021 9:06 AM - StreetInsider Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer September 19, 2021 7:35 AM - PR NewsWire Deutsche Bank Reiterates Hold Rating on Novartis (NOVN:SW) (NVS) September 13, 2021 12:02 PM - StreetInsider Novartis (NOVN:SW) (NVS) PT Lowered to CHF95 at UBS August 25, 2021 4:50 AM - StreetInsider Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates August 5, 2021 6:29 AM - BizWire Form 6-K NOVARTIS AG For: Aug 03 August 3, 2021 6:31 AM - SEC Filing Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events August 2, 2021 9:30 AM - PR NewsWire Novartis (NOVN:SW) (NVS) PT Raised to CHF84 at JPMorgan July 28, 2021 4:15 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Lowered to CHF98 at Morgan Stanley July 28, 2021 2:20 AM - StreetInsider Berenberg Reiterates Buy Rating on Novartis (NOVN:SW) (NVS) July 27, 2021 4:11 AM - StreetInsider Full Article List